The development and application of drugs that target specific molecules expressed on lung cancer cells has garnered increased attention, and remarkable successes have been reported in several NSCLC patient study groups [5], [6], [7], such as a subset of patients with NSCLC testing positive for activating mutations in the epidermal growth factor receptor (EGFR) gene. The gene discussed is EGFR; the disease is lung carcinoma.